Neos pulls off a $72M IPO to push its ADHD drugs forward

Texas biotech Neos Therapeutics ($NEOS) cleared $72 million in an IPO, raising cash to develop some reformulated takes on existing drugs for ADHD. The company priced 4.8 million shares at $15 each, in the middle of its expected range. Neos set aside another 720,000 for its underwriters to cover overallotments, giving it a maximum deal value of more than $83 million. With the proceeds, Neos plans to get a trio of extended-release, orally dissolving treatments on the market. Its lead candidate, containing the same active ingredient as Ritalin, is up for an FDA decision in November, and Neos plans to submit its two amphetamine-based treatments for approval later this year. Release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.